ArticleFrontiers in oncology2025
Case Report: Ovarian endometrioid tumor occurring in a patient with early-stage, low-risk endometrial carcinoma successfully treated by fertility-sparing management.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: Endometrial carcinoma (EC) increasingly affects younger women, prompting interest in fertility-sparing treatments. Although hormonal therapy is a feasible option for carefully selected patients, there remains a substantial risk of recurrence or associated ovarian malignancy. Case presentation: A 35-year-old premenopausal woman reported abnormal uterine bleeding characterized by increased menstrual flow over approximately one year. Diagnosis and intervention: She was diagnosed with stage IA, grade 1 EC managed initially with high-dose oral megestrol acetate followed by a levonorgestrel-releasing intrauterine system due to intolerance. Serial endometrial biopsies demonstrated histologic remission, after which the patient elected definitive surgery with hysterectomy and bilateral salpingectomy while preserving the ovaries. Uterine pathology confirmed absence of residual carcinoma. Follow-up and outcomes: During follow-up, a right adnexal cystic-solid mass was detected and categorized as Ovarian-Adnexal Reporting and Data System (O-RADS) ultrasound category 4, with MRI features raising suspicion. Comprehensive surgical staging confirmed a unilateral low-grade ovarian endometrioid carcinoma with squamous differentiation; staging and peritoneal cytology were negative. The patient recovered uneventfully and remains under surveillance without adjuvant therapy. Lessons: This case highlights the rare occurrence of metachronous ovarian endometrioid carcinoma after successful fertility-sparing and hysterectomy, underscores the importance of shared decision-making regarding ovarian preservation, and supports risk-adapted surveillance strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.